IGF2BP2, EIF4A1 and their targets could serve as potential biomarkers and therapeutic targets for ESCC, offering promising novel approaches for the diagnosis and treatment of ESCC. Here, IGF2BP2 is linked to esophageal squamous cell carcinoma.